Payment overview · 2025
General Payments
$447.24
23 reported records · 7 companies
Healthcare provider profile · identity verified
Alan J Wayne, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · STEVENSON, AL · NPI 1477531283
Verified facts
What the public records show
CMS Open Payments records show Alan J Wayne, M.D. received $447.24 in general payments during 2025 across 23 reported records.
GlaxoSmithKline, LLC. accounted for 33.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Trelegy Ellipta by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Caplyta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $151.52 | 33.9% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $96.96 | 21.7% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $87.35 | 19.5% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $46.79 | 10.5% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.50 | 7.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.57 | 3.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.55 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $447.24 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $151.52 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $87.35 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $77.90 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $59.92 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $51.27 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $46.79 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $33.50 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 147 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 249 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
44 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
249 | 61 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
79 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
147 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 2746 | 281 |
| Gabapentin | Gabapentin | 1169 | 141 |
| Metoprolol Succinate | Metoprolol Succinate | 863 | 198 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 611 | 148 |
| Atorvastatin Calcium | Atorvastatin Calcium | 604 | 174 |
| Alprazolam | Alprazolam | 537 | 62 |
| Lisinopril | Lisinopril | 493 | 129 |
| Pantoprazole Sodium | Pantoprazole Sodium | 457 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 426 | 98 |
| Promethazine Hcl | Promethazine Hcl | 423 | 59 |
| Omeprazole | Omeprazole | 364 | 84 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 359 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 336 | 63 |
| Ondansetron Odt | Ondansetron | 331 | 58 |
| Trazodone Hcl | Trazodone Hcl | 316 | 43 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 257 | 78 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 249 | 61 |
| Montelukast Sodium | Montelukast Sodium | 240 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 239 | 75 |
| Temazepam | Temazepam | 222 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 222 | 34 |
| Buspirone Hcl | Buspirone Hcl | 215 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 215 | 80 |
| Ropinirole Hcl | Ropinirole Hcl | 207 | 31 |
| Furosemide | Furosemide | 202 | 49 |
| Diclofenac Sodium | Diclofenac Sodium | 186 | 53 |
| Azithromycin | Azithromycin | 185 | 113 |
| Pregabalin | Pregabalin | 185 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 177 | 32 |
| Levofloxacin | Levofloxacin | 174 | 104 |
| Carvedilol | Carvedilol | 167 | 48 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 166 | 100 |
| Metformin Hcl | Metformin Hcl | 164 | 38 |
| Clonidine Hcl | Clonidine Hcl | 159 | 41 |
| Eliquis | Apixaban | 159 | 33 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 157 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 157 | 28 |
| Azelastine Hcl | Azelastine Hcl | 154 | 64 |
| Tresiba Flextouch U-200 | Insulin Degludec | 153 | 26 |
| Potassium Chloride | Potassium Chloride | 152 | 37 |
| Amitriptyline Hcl | Amitriptyline Hcl | 148 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 147 | 28 |
| Ozempic | Semaglutide | 147 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 34 |
| Methocarbamol | Methocarbamol | 132 | 44 |
| Losartan Potassium | Losartan Potassium | 128 | 31 |
| Doxepin Hcl | Doxepin Hcl | 123 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 121 | 87 |
| Rizatriptan | Rizatriptan Benzoate | 121 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 115 | 33 |
| Sertraline Hcl | Sertraline Hcl | 111 | 29 |
| Methotrexate | Methotrexate Sodium | 109 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 106 | 17 |
| Celecoxib | Celecoxib | 105 | 32 |
| Torsemide | Torsemide | 104 | 21 |
| Repatha Sureclick | Evolocumab | 100 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 29 |
| Methylprednisolone | Methylprednisolone | 97 | 69 |
| Novolog Flexpen | Insulin Aspart | 96 | 24 |
| Ketoconazole | Ketoconazole | 95 | 32 |
| Meclizine Hcl | Meclizine Hcl | 94 | 21 |
| Humalog Kwikpen U-100 | Insulin Lispro | 90 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 17 |
| Sucralfate | Sucralfate | 89 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 21 |
| Tramadol Hcl | Tramadol Hcl | 88 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 83 | 16 |
| Linzess | Linaclotide | 82 | 26 |
| Entresto | Sacubitril/Valsartan | 79 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 78 | 22 |
| Estradiol | Estradiol | 77 | 15 |
| Minoxidil | Minoxidil | 77 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 77 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 75 | 48 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 17 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 11 |
| Topiramate | Topiramate | 73 | 13 |
| Allopurinol | Allopurinol | 69 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 68 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 68 | 44 |
| Meloxicam | Meloxicam | 66 | 24 |
| Myrbetriq | Mirabegron | 66 | 12 |
| Spironolactone | Spironolactone | 64 | 25 |
| Lovastatin | Lovastatin | 63 | 17 |
| Nitroglycerin | Nitroglycerin | 63 | 22 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 62 | 16 |
| Mounjaro | Tirzepatide | 61 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 13 |
| Naproxen | Naproxen | 59 | 16 |
| Memantine Hcl | Memantine Hcl | 58 | suppressed |
| Baclofen | Baclofen | 56 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 56 | 14 |
| Simvastatin | Simvastatin | 56 | 16 |
| Jardiance | Empagliflozin | 54 | suppressed |
| Lamotrigine | Lamotrigine | 54 | suppressed |
| Clonazepam | Clonazepam | 53 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 14 |
| Nifedipine Er | Nifedipine | 52 | 14 |
| Bupropion Xl | Bupropion Hcl | 50 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 13 |
| Prednisone | Prednisone | 49 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 49 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 46 | suppressed |
| Ibuprofen | Ibuprofen | 46 | 15 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 46 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 46 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 45 | 12 |
| Farxiga | Dapagliflozin Propanediol | 44 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 43 | suppressed |
| Rybelsus | Semaglutide | 43 | suppressed |
| Fluconazole | Fluconazole | 42 | 18 |
| Ofloxacin | Ofloxacin | 42 | 31 |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | suppressed |
| Lidocaine | Lidocaine | 41 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 23 |
| Ranolazine Er | Ranolazine | 39 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Roflumilast | Roflumilast | 35 | suppressed |
| Acyclovir | Acyclovir | 33 | 19 |
| Atenolol | Atenolol | 33 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 33 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Lorazepam | Lorazepam | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Famotidine | Famotidine | 31 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | suppressed |
| Vraylar | Cariprazine Hcl | 31 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 30 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Nystatin | Nystatin | 29 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 25 | 13 |
| Cephalexin | Cephalexin | 24 | 21 |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 24 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Nabumetone | Nabumetone | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 21 | suppressed |
| Haloperidol | Haloperidol | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 16 |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 18 | 12 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 18 | suppressed |
| Belsomra | Suvorexant | 17 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone Dipropionate | 17 | suppressed |
| Cimetidine | Cimetidine | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 16 | suppressed |
| Neupro | Rotigotine | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | 11 |
| Triazolam | Triazolam | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Caplyta | Lumateperone Tosylate | 13 | suppressed |
| Constulose | Lactulose | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 13 |
| Ramipril | Ramipril | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Thioridazine Hcl | Thioridazine Hcl | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Clarithromycin | Clarithromycin | 11 | suppressed |
| Depo-Estradiol | Estradiol Cypionate | 11 | suppressed |
| Paliperidone Er | Paliperidone | 11 | suppressed |
| Unifine Pentips Plus | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $447.24 · 23 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, FANAPT, LEQVIO, Ozempic, REXULTI, Rybelsus, TRELEGY ELLIPTA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error